The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.
about
Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysisTCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemiaMutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cellsMutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessChronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia.Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia.Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia.Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.Treatment options for high-risk chronic lymphocytic leukaemia.CD38 and chronic lymphocytic leukemia: a decade later.p53: a molecular marker for the detection of cancer.Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia.Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaPrior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia.High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemiaThe tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management.Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia.High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray.Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
P2860
Q24186840-7BD74483-6321-4DD2-BCE8-7C5BDA421ADCQ26773053-B0824516-65F5-452D-A399-A64E80B361A2Q27851685-AFE3293F-12CB-4323-9A69-E090D39107E1Q28744086-B0C5BDFF-9D8D-45BB-A892-416DE4F48823Q29013141-B6AE82EC-0467-4C3C-BD7A-FE4A97C7C75BQ30538420-F86C5F0F-06B7-481A-AFE2-8CC8DE4BD78FQ34012864-5F0666BF-0F48-4853-8326-21F9FB5DC676Q34056768-D5333C4D-A23E-4EC6-B017-36EB905455CDQ34217900-8792BEF0-FD43-4C69-92AC-E9EC0CED3FD9Q34418874-C8B6AC44-E62D-458E-8979-C6AF3A95C9D4Q34750656-FAD59459-4BC2-49C2-8C61-9E369AC4B83DQ35183015-0AD27223-D918-409A-A570-DED330125C39Q36177909-12940853-ED5A-45A6-987A-800EA9239752Q36227244-9A2A9778-4F1D-4E64-84C9-BE0F2A5E6B37Q36612587-52A2A7D3-6F91-436E-9731-D0A6A910A46EQ36615126-DCFC5CA7-C3E8-460D-9054-6CB39A41FB69Q37248542-BE18449D-6D70-462E-A90D-3E05121FE9E7Q37273662-D485A83F-8E8B-4F77-87AF-30882576487DQ37343931-40B97678-E78E-4E4F-ABF3-E332F0E8D0F9Q37369963-412C94DB-D1D1-4F6A-8816-BAC3956A6A04Q37427988-C50FF6D4-112E-4287-962A-FFC0CF8B1E93Q37594546-B25A3EF0-E61E-49AD-A376-972102EDE549Q37866334-E6801F5E-8510-4E63-AE9E-AF3D1111AE06Q37874926-199A2873-D4C4-4303-9337-A3BCFE052514Q38101382-FEEC30C9-E172-4B28-B321-A5BE2FFDCBF3Q38254406-825B2AB3-19E6-44DA-A752-2AABCCEE3114Q38365378-21B4A39E-95DB-4DC2-8151-C9A08F864626Q38826234-817EE372-513A-4B91-A676-21B11E11B233Q39169789-E451727D-FCC7-4293-B23D-14621DA9831DQ40817325-5E1C3C17-C4C6-45C2-8B40-D8F8EB5F34B3Q44447816-C70B75E6-6EDF-43CA-90DC-2858A2880182Q45901753-3A4D93FC-E903-487A-B420-5B74FB7B909AQ46444068-F67D3847-654A-47CE-95AE-ADDA3513FCAFQ47137610-EBB6DA52-3BEC-4A1E-A735-E2A9D7231A60Q50110556-0BDF643A-D003-4E7B-AEE9-36EE439BCDF8
P2860
The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The role of prognostic factors ...... chronic lymphocytic leukemia.
@en
type
label
The role of prognostic factors ...... chronic lymphocytic leukemia.
@en
prefLabel
The role of prognostic factors ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P356
P1433
P1476
The role of prognostic factors ...... chronic lymphocytic leukemia.
@en
P2093
O'Brien SM
Pettitt AR
Stilgenbauer S
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404802
P577
2007-06-14T00:00:00Z